主要文書

すべての文書を表示

1224551

USP

ドセタキセル

Name: ドセタキセル
Brand: USP

United States Pharmacopeia (USP) Reference Standard

別名:

ドセタキセル三水和物

ログインで組織・契約価格をご覧ください。

サイズを選択してください

表示を変更する

この商品について

実験式（ヒル表記法）:

C₄₃H₅₃NO₁₄ · 3H₂O

CAS番号:

148408-66-6

分子量:

861.93

MDL number:

MFCD26960948

UNSPSC Code:

41116107

NACRES:

NA.24

テクニカルサービス

お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。

お手伝いします

特性

grade

pharmaceutical primary standard

API family

docetaxel

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

N([C@H]([C@@H](O)C(=O)O[C@H]2C[C@]3([C@H]([C@@H]5[C@]6([C@H](OC6)C[C@@H]([C@]5(C(=O)[C@@H](C(=C2C)C3(C)C)O)C)O)OC(=O)C)OC(=O)c4ccccc4)O)c1ccccc1)C(=O)OC(C)(C)C.O.O.O

InChI

1S/C43H53NO14.3H2O/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45;;;/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52);3*1H2/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+;;;/m0.../s1

InChI key

XCDIRYDKECHIPE-QHEQPUDQSA-N

詳細

General description

この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。

Application

Docetaxel USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Also, for use with USP monograph such as Docetaxel Injection

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under ドセタキセル

pictograms

GHS08,GHS07

signalword

Danger

hcodes

H319,H360F

pcodes

P201 - P280 - P305 + P351 + P338 - P308 + P313

Hazard Classifications

Eye Irrit. 2 - Repr. 1B

保管分類

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

最新バージョンのいずれかを選択してください：

試験成績書（COA）

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせくださいカスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.

Monisha Sudarshan et al.

Annals of surgical oncology, 22(1), 324-330 (2014-07-16)

We have previously identified Docetaxel, Cisplatin, and 5FU (DCF) as a safe, tolerable, and effective regimen in the neoadjuvant setting for locally advanced adenocarcinoma (ADC) of the esophagus and esophagogastric junction (EGJ). We hypothesized that DCF combined with enhanced surgical

Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.

Isamu Okamoto et al.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 10(2), 346-352 (2014-10-10)

This phase I, open-label study evaluated the safety/tolerability and maximum tolerated dose of second-line nintedanib combined with docetaxel in Japanese patients with advanced non-small-cell lung cancer. Eligible patients received docetaxel 60 or 75 mg/m(2) (day 1) plus nintedanib 100, 150

Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial.

Fred Saad et al.

European urology, 67(2), 223-230 (2014-08-31)

Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer (PCa) after docetaxel in the randomised, phase 3, double-blind, placebo-controlled, multinational Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy (AFFIRM) trial (NCT00974311). Prostate-specific antigen (PSA)